Exploring Knowledge Graphs for COVID-19 Drug Discovery
Jul. 28, 2021- By: Jacob Al-Saleem
Courtesy ofChemical Abstracts Service (CAS)
Today, there are only a few therapies approved to treat COVID-19, but while novel therapies can take decades and billions of dollars to develop, are there opportunities to repurpose existing drugs for new therapies? Our latest whitepaper showcases how CAS Knowledge Graphs reveal new connections and insights that identify drugs to potentially repurpose.
Drug repurposing is critical for faster development of therapies. However, assembling all the critical information and connections around new proteins, viruses, targets, pathways, and clinical information can be challenging. This demonstrates how CAS Knowledge Graphs can identify top clinical candidates to repurpose for COVID-19 therapies.
Most popular related searches
COVID 19
sars-cov-2
drug discovery
small molecule drug
small-molecule drug
small-molecule drug candidate
cytokine storm
drug candidate
COVID-19 treatment
gene expression
clinical trial
Parkinson`s disease
cancer disease
blood typing
inflammatory response
immune response
vascular inflammation
blood coagulation
drug identification
clinical data
autoimmune disease
rare disease
biomedical data
tyrosine kinase inhibitor
cytokine
biomedical
drug molecule
therapeutic potential
COVID risk
Alzheimer
drug therapy
Alzheimer disease
electrographic flow system
docetaxel
autoimmune
coronavirus
blood processing
Stay in the loop!
Select your areas of interest to receive industry updates.